Clinical Trial

Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients

Study acronym: PRIMARY
Recruiting
View on ClinicalTrials.gov →
Summary
To conduct a multicenter, prospective observational cohort study to investigate first-line immunotherapy patterns and clinical outcomes in NDMM patients in China. Leveraging the extensive patient resources of China's large center for blood disorders, the investigator will recruit approximately 500 NDMM patients to establish an NDMM patient cohort. The investigator will collect data on disease characteristics, treatment patterns, and clinical outcomes through one year of clinical follow-up. Further long-term follow-up is needed to obtain survival status and causes of death, so as to provide essential evidence for optimizing and improving patients' prognosis in clinical individualized treatment.
Trial Details
NCT Number NCT07296627
Lead Sponsor Peking University People's Hospital
Conditions Newly Diagnosed Multiple Myeloma (NDMM)
Enrollment 500 participants
Start Date 2025-07-16
Primary Completion 2027-07-15 (estimated)
Study Completion 2027-11-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-22